20.500.12556/DiRROS-24311 Long-term outcomes of reduced-dose bleomycin in electrochemotherapy for basal cell carcinoma in elderly patients Electrochemotherapy (ECT) is a minimally invasive treatment option for basal cell carcinoma (BCC), which is particularly advantageous in the elderly population. This study evaluated the long-term effects of treating BCC in older patients using ECT with a reduced dose of bleomycin (10,000 IU/m2) and compared the results to patients who received the standard dose of bleomycin (15,000 IU/m2). The retrospective analysis included 116 patients aged over 65 years with 257 histologically confirmed BCCs. Tumors were treated with either the standard dose (n = 82) or the reduced dose (n = 175) of bleomycin. The results showed that the recurrence rate was comparable between the groups, particularly in the first year after treatment. The reduced-dose group exhibited a greater recurrence rate after the first year, which may be attributed to a weaker local immune response due to the de-escalated dose of bleomycin. Nonetheless, administering a standard bleomycin dosage as a salvage treatment in the event of recurrence proved highly effective. These findings suggest that ECT with a reduced bleomycin dose is a viable option for treating BCC in elderly patients, particularly those with shorter life expectancy. bleomycin electrochemotherapy head and neck nonmelanoma skin cancer bleomicin elektrokemoterapija glava in vrat nemelanomski rak kože true false true Angleški jezik Slovenski jezik Neznano 2025-11-25 14:43:52 2025-11-25 14:43:53 2025-11-26 03:52:46 0000-00-00 00:00:00 2025 0 0 Nasl. z nasl. zaslona; Opis vira z dne 23. 4. 2025; str. 1-7 no. 1 Vol. 15 2025 0000-00-00 Zaloznikova Objavljeno apc 0000-00-00 0000-00-00 0000-00-00 616-006 2045-2322 10.1038/s41598-025-93104-3 234048259 RAZ_Groselj_Ales_2025.pdf RAZ_Groselj_Ales_2025.pdf 1 CEAA737C686B061EF4C459C8DB423C80 7b00da73aecae7de264233eed40b4e8ef08aa50f9077576fdf9c653b308b23ca ea208919-ca04-11f0-94a7-001a4af901a5 https://dirros.openscience.si/Dokument.php?lang=slv&id=36210 https://www.nature.com/articles/s41598-025-93104-3 1 cb50173d-ca04-11f0-94a7-001a4af901a5 https://dirros.openscience.si/Dokument.php?lang=slv&id=36209 Univerzitetni klinični center Ljubljana 0 0 0